These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 20135198)

  • 21. GPNMB methylation: a new marker of potentially carcinogenic colon lesions.
    Ashktorab H; Rahi H; Nouraie M; Shokrani B; Lee E; Haydari T; Laiyemo AO; Siegel P; Brim H
    BMC Cancer; 2018 Nov; 18(1):1068. PubMed ID: 30400781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.
    Weisenberger DJ; Liang G; Lenz HJ
    Oncogene; 2018 Feb; 37(5):566-577. PubMed ID: 28991233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accumulation of aberrant DNA methylation during colorectal cancer development.
    Sakai E; Nakajima A; Kaneda A
    World J Gastroenterol; 2014 Jan; 20(4):978-87. PubMed ID: 24574770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression.
    Muthamilselvan S; Raghavendran A; Palaniappan A
    PLoS One; 2022; 17(2):e0249151. PubMed ID: 35202405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    Kordowski F; Kolarova J; Schafmayer C; Buch S; Goldmann T; Marwitz S; Kugler C; Scheufele S; Gassling V; Németh CG; Brosch M; Hampe J; Lucius R; Röder C; Kalthoff H; Siebert R; Ammerpohl O; Reiss K
    BMC Cancer; 2018 Aug; 18(1):796. PubMed ID: 30081852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter CpG island methylation markers in colorectal cancer: the road ahead.
    Draht MX; Riedl RR; Niessen H; Carvalho B; Meijer GA; Herman JG; van Engeland M; Melotte V; Smits KM
    Epigenomics; 2012 Apr; 4(2):179-94. PubMed ID: 22449189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis.
    Li DJ; Feng ZC; Li XR; Hu G
    World J Gastroenterol; 2018 Nov; 24(44):5013-5024. PubMed ID: 30510376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
    Savio AJ; Bapat B
    Methods Mol Biol; 2015; 1238():103-24. PubMed ID: 25421657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of DNA methylation in colorectal cancer].
    Tokarz P; Błasiak J
    Postepy Biochem; 2013; 59(3):267-79. PubMed ID: 24364209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!
    van Vlodrop IJ; Niessen HE; Derks S; Baldewijns MM; van Criekinge W; Herman JG; van Engeland M
    Clin Cancer Res; 2011 Jul; 17(13):4225-31. PubMed ID: 21558408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer.
    Kim SJ; Tae CH; Hong SN; Min BH; Chang DK; Rhee PL; Kim JJ; Kim HC; Kim DH; Kim YH
    Mol Carcinog; 2015 Dec; 54(12):1748-57. PubMed ID: 25620232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic regulation of microRNA expression in colorectal cancer.
    Bandres E; Agirre X; Bitarte N; Ramirez N; Zarate R; Roman-Gomez J; Prosper F; Garcia-Foncillas J
    Int J Cancer; 2009 Dec; 125(11):2737-43. PubMed ID: 19521961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.
    Karpinski P; Walter M; Szmida E; Ramsey D; Misiak B; Kozlowska J; Bebenek M; Grzebieniak Z; Blin N; Laczmanski L; Sasiadek MM
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):201-8. PubMed ID: 23175427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant Methylation of FOXE1 Contributes to a Poor Prognosis for Patients with Colorectal Cancer.
    Sugimachi K; Matsumura T; Shimamura T; Hirata H; Uchi R; Ueda M; Sakimura S; Iguchi T; Eguchi H; Masuda T; Morita K; Takenaka K; Maehara Y; Mori M; Mimori K
    Ann Surg Oncol; 2016 Nov; 23(12):3948-3955. PubMed ID: 27271927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers.
    An B; Kondo Y; Okamoto Y; Shinjo K; Kanemitsu Y; Komori K; Hirai T; Sawaki A; Tajika M; Nakamura T; Yamao K; Yatabe Y; Fujii M; Murakami H; Osada H; Tani T; Matsuo K; Shen L; Issa JP; Sekido Y
    Int J Cancer; 2010 Nov; 127(9):2095-105. PubMed ID: 20131317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathways in colorectal cancer.
    Al-Sohaily S; Biankin A; Leong R; Kohonen-Corish M; Warusavitarne J
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1423-31. PubMed ID: 22694276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.
    Belshaw NJ; Elliott GO; Williams EA; Bradburn DM; Mills SJ; Mathers JC; Johnson IT
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1495-501. PubMed ID: 15342451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.
    Hellebrekers DM; Lentjes MH; van den Bosch SM; Melotte V; Wouters KA; Daenen KL; Smits KM; Akiyama Y; Yuasa Y; Sanduleanu S; Khalid-de Bakker CA; Jonkers D; Weijenberg MP; Louwagie J; van Criekinge W; Carvalho B; Meijer GA; Baylin SB; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2009 Jun; 15(12):3990-7. PubMed ID: 19509152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
    Meng H; Li W; Boardman LA; Wang L
    BMC Cancer; 2018 Apr; 18(1):433. PubMed ID: 29661177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant hypermethylation of OGDHL gene promoter in sporadic colorectal cancer.
    Khalaj-Kondori M; Hosseinnejad M; Hosseinzadeh A; Behroz Sharif S; Hashemzadeh S
    Curr Probl Cancer; 2020 Feb; 44(1):100471. PubMed ID: 30904169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.